Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses.

Biotechnology

Education

Nuvalent

James Porter

Philip Engel

Wenzhe Fan

José Rios Lizarraga

Jeffrey Lee

Henry Pelish

Joshua Horan

Deb Miller

Alex Balcom

John Soglia

Christopher Turner

Darlene Noci

Jessie Lin

Shannon Dauksis

Kristi Byrnes

Matthew Metivier

Leadership Team

Teams at Nuvalent

Leadership Team